BR0212069A - Agentes antidiabéticos orais - Google Patents
Agentes antidiabéticos oraisInfo
- Publication number
- BR0212069A BR0212069A BR0212069-0A BR0212069A BR0212069A BR 0212069 A BR0212069 A BR 0212069A BR 0212069 A BR0212069 A BR 0212069A BR 0212069 A BR0212069 A BR 0212069A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- oral antidiabetic
- antidiabetic agents
- compounds
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
"AGENTES ANTIDIABéTICOS ORAIS". A presente invenção refere-se a compostos de Fórmula (I): em que A, X, Q, Y, B, D, Z e E têm quaisquer dos valores definidos na descrição, e seus sais farmaceuticamente aceitáveis, que são úteis como agentes antidiabéticos. São também descritas composições farmacêuticas compreendendo um ou mais compostos de Fórmula I, processos para a preparação de compostos de Fórmula I e intermediários úteis para a preparação de compostos de Fórmula I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31572801P | 2001-08-29 | 2001-08-29 | |
| PCT/IB2002/002843 WO2003018553A1 (en) | 2001-08-29 | 2002-07-15 | Oral antidiabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212069A true BR0212069A (pt) | 2004-07-20 |
Family
ID=23225787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212069-0A BR0212069A (pt) | 2001-08-29 | 2002-07-15 | Agentes antidiabéticos orais |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1423363B1 (pt) |
| JP (1) | JP2005504778A (pt) |
| KR (1) | KR20040044515A (pt) |
| CN (1) | CN1558897A (pt) |
| AP (1) | AP2002002616A0 (pt) |
| AR (1) | AR036301A1 (pt) |
| AT (1) | ATE323674T1 (pt) |
| BG (1) | BG108597A (pt) |
| BR (1) | BR0212069A (pt) |
| CA (1) | CA2458621A1 (pt) |
| CZ (1) | CZ2004272A3 (pt) |
| DE (1) | DE60210784T2 (pt) |
| EA (1) | EA200400140A1 (pt) |
| EC (1) | ECSP044999A (pt) |
| EE (1) | EE200400075A (pt) |
| ES (1) | ES2260456T3 (pt) |
| GT (1) | GT200200175A (pt) |
| HN (1) | HN2002000242A (pt) |
| HR (1) | HRP20040164A2 (pt) |
| HU (1) | HUP0401620A2 (pt) |
| IL (1) | IL159886A0 (pt) |
| IS (1) | IS7114A (pt) |
| MA (1) | MA27135A1 (pt) |
| MX (1) | MXPA04001968A (pt) |
| NO (1) | NO20040881L (pt) |
| OA (1) | OA12653A (pt) |
| PA (1) | PA8553701A1 (pt) |
| PE (1) | PE20030563A1 (pt) |
| PL (1) | PL369569A1 (pt) |
| SK (1) | SK1182004A3 (pt) |
| SV (1) | SV2003001213A (pt) |
| TN (1) | TNSN04038A1 (pt) |
| UY (1) | UY27424A1 (pt) |
| WO (1) | WO2003018553A1 (pt) |
| ZA (1) | ZA200400374B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059907A1 (en) * | 2002-01-17 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof |
| PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
| US7592361B2 (en) * | 2003-04-28 | 2009-09-22 | Bayer Pharmaceuticals Corporation | Indole acetic acid derivatives and their use as pharmaceutical agents |
| JP2007516171A (ja) * | 2003-06-27 | 2007-06-21 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | N2−アルキル化1,2,3−トリアゾールの調製 |
| RU2344135C2 (ru) * | 2003-07-02 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar |
| KR20130023381A (ko) * | 2003-07-17 | 2013-03-07 | 플렉시콘, 인코퍼레이티드 | Ppar 활성 화합물 |
| KR100761615B1 (ko) * | 2003-11-05 | 2007-10-04 | 에프. 호프만-라 로슈 아게 | Ppar 활성화제로서 헤테로아릴 유도체 |
| WO2005056522A2 (en) | 2003-12-04 | 2005-06-23 | National Health Research Institutes | Indole compounds |
| CA2545767A1 (en) * | 2003-12-11 | 2005-06-30 | Galderma Research & Development, S.N.C. | Novel compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions |
| FR2863610B1 (fr) * | 2003-12-11 | 2006-01-20 | Galderma Res & Dev | NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES |
| BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
| EP1725546B1 (en) * | 2004-03-09 | 2008-10-08 | F.Hoffmann-La Roche Ag | Pyrazolyl indolyl derivatives as ppar activators |
| US7405236B2 (en) * | 2004-08-16 | 2008-07-29 | Hoffman-La Roche Inc. | Indole derivatives comprising an acetylene group |
| TW200724138A (en) * | 2005-03-29 | 2007-07-01 | Sk Corp | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use |
| PE20080188A1 (es) * | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
| PL2014652T3 (pl) | 2006-04-18 | 2015-02-27 | Nippon Chemiphar Co | Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów |
| AU2013202514B2 (en) * | 2006-04-18 | 2015-09-17 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| AU2009236877B2 (en) | 2008-04-15 | 2014-01-23 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
| FR2976943B1 (fr) | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| FR2976942B1 (fr) | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| WO2013139341A1 (en) * | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| WO2013185766A1 (en) * | 2012-06-15 | 2013-12-19 | Syddansk Universitet | Gpr120 receptor modulators |
| WO2025141118A1 (en) * | 2023-12-27 | 2025-07-03 | Institut National de la Santé et de la Recherche Médicale | Arylalkyloxyindole compounds and derivatives and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| ATE286032T1 (de) * | 1998-04-23 | 2005-01-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
| WO2000023425A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6274608B1 (en) * | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
| EE200100540A (et) * | 1999-04-28 | 2002-12-16 | Dr. Reddy's Research Foundation | Asendusega bitsüklilised heterotsüklid, nende valmistamismeetod ja kasutamine rasvumisvastaste ja hüpokolesteroleemsete agensitena |
| EP1210345B1 (en) * | 1999-09-08 | 2004-03-03 | Glaxo Group Limited | Oxazole ppar antagonists |
-
2002
- 2002-07-15 CN CNA028216350A patent/CN1558897A/zh active Pending
- 2002-07-15 WO PCT/IB2002/002843 patent/WO2003018553A1/en not_active Ceased
- 2002-07-15 PL PL02369569A patent/PL369569A1/xx not_active Application Discontinuation
- 2002-07-15 HU HU0401620A patent/HUP0401620A2/hu unknown
- 2002-07-15 OA OA1200400053A patent/OA12653A/en unknown
- 2002-07-15 DE DE60210784T patent/DE60210784T2/de not_active Expired - Fee Related
- 2002-07-15 EP EP02745739A patent/EP1423363B1/en not_active Expired - Lifetime
- 2002-07-15 HR HR20040164A patent/HRP20040164A2/hr not_active Application Discontinuation
- 2002-07-15 CA CA002458621A patent/CA2458621A1/en not_active Abandoned
- 2002-07-15 AT AT02745739T patent/ATE323674T1/de not_active IP Right Cessation
- 2002-07-15 MX MXPA04001968A patent/MXPA04001968A/es unknown
- 2002-07-15 CZ CZ2004272A patent/CZ2004272A3/cs unknown
- 2002-07-15 ES ES02745739T patent/ES2260456T3/es not_active Expired - Lifetime
- 2002-07-15 JP JP2003523217A patent/JP2005504778A/ja not_active Withdrawn
- 2002-07-15 EA EA200400140A patent/EA200400140A1/ru unknown
- 2002-07-15 EE EEP200400075A patent/EE200400075A/xx unknown
- 2002-07-15 KR KR10-2004-7003019A patent/KR20040044515A/ko not_active Ceased
- 2002-07-15 IL IL15988602A patent/IL159886A0/xx unknown
- 2002-07-15 SK SK118-2004A patent/SK1182004A3/sk not_active Application Discontinuation
- 2002-07-15 BR BR0212069-0A patent/BR0212069A/pt not_active IP Right Cessation
- 2002-07-15 EP EP05104581A patent/EP1577305A1/en not_active Withdrawn
- 2002-08-27 HN HN2002000242A patent/HN2002000242A/es unknown
- 2002-08-27 PA PA20028553701A patent/PA8553701A1/es unknown
- 2002-08-27 UY UY27424A patent/UY27424A1/es not_active Application Discontinuation
- 2002-08-27 AR ARP020103209A patent/AR036301A1/es unknown
- 2002-08-27 PE PE2002000822A patent/PE20030563A1/es not_active Application Discontinuation
- 2002-08-28 GT GT200200175A patent/GT200200175A/es unknown
- 2002-08-28 SV SV2002001213A patent/SV2003001213A/es not_active Application Discontinuation
- 2002-08-29 AP APAP/P/2002/002616A patent/AP2002002616A0/en unknown
-
2004
- 2004-01-15 IS IS7114A patent/IS7114A/is unknown
- 2004-01-16 ZA ZA2004/00374A patent/ZA200400374B/en unknown
- 2004-02-19 MA MA27537A patent/MA27135A1/fr unknown
- 2004-02-24 BG BG108597A patent/BG108597A/bg unknown
- 2004-02-25 TN TNP2004000038A patent/TNSN04038A1/fr unknown
- 2004-02-27 NO NO20040881A patent/NO20040881L/no not_active Application Discontinuation
- 2004-03-03 EC EC2004004999A patent/ECSP044999A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0212069A (pt) | Agentes antidiabéticos orais | |
| BR0210028A (pt) | Agentes antibacterianos | |
| BR0108893A (pt) | Composição farmacêutica, composto e processo de preparação de compostos | |
| BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
| BRPI0417458A (pt) | compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| BR0211289A (pt) | Derivados de dolastatina 10 | |
| BRPI0413469A (pt) | derivados de piperazina para o tratamento de infecções por hiv | |
| BR0001468A (pt) | ácidos dioxiciclopentil hidroxânicos | |
| BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
| BR0205889A (pt) | Pirazolopirimidinas como agentes tepapêuticos | |
| BG66094B1 (bg) | Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства | |
| EE200300417A (et) | Asendatud aminometüülrühma sisaldavad N-(arüülsulfonüül)beetaaminohappe derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
| UY27368A1 (es) | Nuevos compuestos | |
| BR9908545A (pt) | Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica | |
| BR0316081A (pt) | Derivados de 2-piridona como inibidores de elastase de neutrófilo | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| BR0010938A (pt) | Derivados da 13-metil eritromicina | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| BRPI0409465A (pt) | derivados de carboxamida como agentes antidiabéticos | |
| BR9905089A (pt) | Derivados macrolìdeos | |
| BR0101230A (pt) | Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina | |
| BR0110357A (pt) | Sais bicìclicos e n-aciclados de aminas imidazo - 3 e imidazo -5 | |
| BR0215016A (pt) | Piridoquinoxalinas antivirìcas | |
| IL157540A (en) | Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 6A,7A, 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |